AbbVie : ABBV

All AbbVie Articles

580 Articles

Vandita Jadeja | Apr 30, 2026 at 10:40 AM EDT

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but…

Lee Jackson | Apr 30, 2026 at 7:49 AM EDT

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices…

John Seetoo | Apr 25, 2026 at 6:35 AM EDT

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by…

Vandita Jadeja | Apr 23, 2026 at 4:04 PM EDT

These 5 Stocks Pay You Even When You’re Sleeping

Market volatility in 2026 has reminded investors that earned income alone is fragile. When tariff fears rattle equities and economic…

David Beren | Apr 21, 2026 at 3:34 PM EDT

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Gabelli Dividend & Income Trust (NYSE:GDV) trades near $29 and pays a $0.15 monthly distribution, up from $0.11 per month…

David Moadel | Apr 21, 2026 at 10:30 AM EDT

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating…

Vandita Jadeja | Apr 20, 2026 at 10:37 AM EDT

Why I Can’t Stop Buying AbbVie Stock

AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The…

Vandita Jadeja | Apr 17, 2026 at 10:22 AM EDT

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record…

David Moadel | Apr 7, 2026 at 9:58 AM EDT

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan…

Vandita Jadeja | Apr 6, 2026 at 12:15 PM EDT

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two…

Lee Jackson | Apr 2, 2026 at 8:10 AM EDT

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for…

John Seetoo | Mar 27, 2026 at 11:49 AM EDT

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend…

Michael Williams | Mar 26, 2026 at 2:32 PM EDT

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT),…

John Seetoo | Mar 25, 2026 at 1:30 PM EDT

VIG Returned 223% Over 10 Years and Still Costs Almost Nothing

A 1.5% yield sounds unimpressive until you realize the dividend check doubles roughly every seven years. That is the premise…

Chris MacDonald | Mar 20, 2026 at 10:02 AM EDT

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

Growth investing has had a choppy start to 2026. The major growth benchmarks are down in the low single digits…

1 2 3 4 … 39

AbbVie : ABBV

All AbbVie Articles

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

These 5 Stocks Pay You Even When You’re Sleeping

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

VIG Returned 223% Over 10 Years and Still Costs Almost Nothing

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks

Buy, Hold, or Sell: Walmart Makes Sense as a Buy at $115

Family Limited Partnerships: How to Lock In $4 Million in Valuation Discounts Before Congress Acts Again

Family Limited Partnerships: How to Lock In $4 Million in Valuation Discounts Before Congress Acts Again

The Severance Negotiation Move That Cut a 56-Year-Old VP's Tax Bill on Her $480,000 Package by $112,000

Warren Buffett: “People Still Don’t Want to Think It Will Work”

This Midstream ETF Yields 9.4% While Sidestepping K-1 Tax Forms

AbbVie : ABBV

All AbbVie Articles

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

These 5 Stocks Pay You Even When You’re Sleeping

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

VIG Returned 223% Over 10 Years and Still Costs Almost Nothing

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks

Buy, Hold, or Sell: Walmart Makes Sense as a Buy at $115

Family Limited Partnerships: How to Lock In $4 Million in Valuation Discounts Before Congress Acts Again

Featured Reads

Family Limited Partnerships: How to Lock In $4 Million in Valuation Discounts Before Congress Acts Again

The Severance Negotiation Move That Cut a 56-Year-Old VP's Tax Bill on Her $480,000 Package by $112,000